Link to Full Article Product designed to provide safer, more immediate treatment option for patients London and Cambridge, January 9, 2020 – Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing […]

Link to Full Article Cambridge, UK., 22 October 2019: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organization funding type 1 diabetes (T1D) research. Under this collaboration, Arecor and JDRF will […]

Link to Full Article Cambridge, UK., 9th July 2019: Arecor Ltd (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company. Under this […]

Link to Full Article Cambridge, UK., 7th May 2019: Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces dosing of the first patient in its Phase I clinical trial for its ultra-rapid acting […]

Hot on the heels of our first clinical trials approval, Arecor is delighted to be listed in Business Weekly’s ‘Killer50’, as a leading lifescience innovator. Please see the listing and feature here on Page 12: Link